Working Group: Topics

Topics Under Review

Use of Genomic Profiling to Assess Risk for Cardiovascular Disease and Identify Individualized Prevention Strategies

Disorder: Cardiovascular Disease (CVD)

Test: DNA-based testing panels that identify variants in multiple genes associated with risk for specific cardiovascular disorders (e.g., coronary artery disease, myocardial infarction, stroke). 

Clinical Scenario:  An individual’s risk for CVD is based on a combination of genetic and environmental factors. The results of multigene test panels that identify variations in certain genes can be used, in some cases along with family history and/or lifestyle information, to determine an individual’s risk for CVD. It has been proposed that individuals testing positive for genetic variants associated with specific cardiovascular disorders may be more motivated to seek and be compliant with pharmaceutical interventions (e.g., cholesterol or blood pressure lowering drugs), or to adopt recommended lifestyle changes (e.g., diet, exercise), in order to reduce their risk of CVD. 

EGAPP considerations for topic selection

• Key criteria: Prevalence and severity of CVD; testing is offered through both clinical and direct-to-consumer models, each with unique considerations.
• Other Considerations: Estimating risk of CVD based on variants in multiple genes, individually and in combination, challenges risk assessment and EGAPP evidence review methods.

Evidence Report: pending
EGAPP Recommendation: pending
See other products: pending
Last revised: 06/27/07

DISCLAIMER: This information is NOT intended to be a complete or comprehensive review but just an introduction to the topic. The topics listed are NOT endorsed by nor should Imply Endorsement of the test or Manufacturer by EGAPP. Selection of any topic by EGAPP for an evidence review may result in changes to the disorder, test technology, clinical scenario, and EGAPP considerations for selection.